IRIS
PUPPO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.536
AS - Asia 1.908
NA - Nord America 946
SA - Sud America 171
AF - Africa 31
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 22.595
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.209
US - Stati Uniti d'America 888
SG - Singapore 797
CN - Cina 565
VN - Vietnam 293
FR - Francia 151
BR - Brasile 100
HK - Hong Kong 66
BD - Bangladesh 47
DE - Germania 38
FI - Finlandia 34
AR - Argentina 30
MX - Messico 24
JP - Giappone 22
IQ - Iraq 18
CA - Canada 17
GB - Regno Unito 15
ID - Indonesia 14
IN - India 13
CH - Svizzera 12
MA - Marocco 11
NL - Olanda 11
RU - Federazione Russa 11
TH - Thailandia 11
ES - Italia 10
IE - Irlanda 10
ZA - Sudafrica 9
PY - Paraguay 8
TR - Turchia 8
VE - Venezuela 8
UA - Ucraina 7
CO - Colombia 6
EC - Ecuador 6
PH - Filippine 6
PK - Pakistan 6
PL - Polonia 6
JM - Giamaica 5
JO - Giordania 5
PE - Perù 5
SA - Arabia Saudita 5
KR - Corea 4
MY - Malesia 4
OM - Oman 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DZ - Algeria 3
GR - Grecia 3
HN - Honduras 3
IR - Iran 3
MD - Moldavia 3
TW - Taiwan 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
CL - Cile 2
DO - Repubblica Dominicana 2
EG - Egitto 2
LT - Lituania 2
MT - Malta 2
NP - Nepal 2
PR - Porto Rico 2
RO - Romania 2
TN - Tunisia 2
UZ - Uzbekistan 2
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
HR - Croazia 1
LC - Santa Lucia 1
LV - Lettonia 1
LY - Libia 1
ML - Mali 1
NG - Nigeria 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SE - Svezia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 22.595
Salva come PNG Salva come JPEG
Città #
Genova 12.123
Genoa 4.214
Rapallo 1.549
Vado Ligure 1.215
Singapore 370
San Jose 308
Lauterbourg 143
Beijing 105
Ashburn 94
Ho Chi Minh City 93
Hong Kong 62
Hanoi 58
New York 52
Bordighera 42
Santa Clara 39
Helsinki 33
Frankfurt am Main 30
Council Bluffs 28
Los Angeles 18
Tokyo 17
Mexico City 16
Tianjin 15
Buffalo 13
Haiphong 13
Da Nang 12
Zurich 12
Orem 11
St Louis 11
Amsterdam 10
Dublin 10
Chicago 9
São Paulo 9
Madrid 8
Milan 8
Boardman 7
Boston 7
Shanghai 7
Baghdad 6
Charlotte 6
Dallas 6
Rio de Janeiro 6
Rome 6
Warsaw 6
Amman 5
Bangkok 5
Biên Hòa 5
Bắc Ninh 5
Can Tho 5
Lima 5
Phoenix 5
Acalanes Ridge 4
Chennai 4
City of London 4
Dhaka 4
Kingston 4
Montreal 4
Thái Nguyên 4
Asunción 3
Bogotá 3
Bắc Giang 3
Cape Town 3
Curitiba 3
Des Moines 3
Guangzhou 3
Kuala Lumpur 3
Kyiv 3
La Paz 3
London 3
Paris 3
Poplar 3
Quito 3
Quảng Ngãi 3
San Francisco 3
San Pedro Sula 3
Sarnthein 3
Serrenti 3
Vinh 3
Washington 3
Agadir 2
Ankara 2
Araranguá 2
Augusta 2
Cardiff 2
Caxias do Sul 2
Changchun 2
Charleston 2
Ciudad del Este 2
Córdoba 2
Dammam 2
Detroit 2
Erbil 2
Jeddah 2
Johannesburg 2
Ksar Hellal 2
Lahore 2
Lancaster 2
Las Vegas 2
Manchester 2
Manila 2
Melbourne 2
Totale 20.977
Salva come PNG Salva come JPEG
Nome #
Infection risk associated with anti-TNF-α agents: A review 238
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 228
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 225
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 210
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 207
Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro 205
Vaccine-preventable infections in Systemic Lupus Erythematosus 200
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 200
ACUTE CARDIAC FAILURE AND IGA NEPHROPATHY: AN UNCOMMON SLE ONSET 200
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 199
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 196
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 193
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 193
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 192
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 190
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 186
The antiphospholipid syndrome: from pathophysiology to treatment 185
Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. 181
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 181
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 175
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 174
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients 174
General surgery, translational lymphology and lymphatic surgery 174
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 173
Immunoregulatory Role of HLA-G in Allergic Diseases 172
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 172
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 171
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 171
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 167
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 167
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 166
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 166
Defective expression and function of the leukocyte associated ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients 161
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 159
An Uncommon Presentation of Pancreatic Carcinoma 159
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 158
In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? 158
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 158
Immune cell circulating subsets are affected by gonadal function. 158
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. 156
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 154
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes 152
Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions. 152
Update upon the infection risk in patients receiving TNF alpha inhibitors 152
Genetic factors and systemic sclerosis 152
Effects of antagomiRs on different lung diseases in human, cellular, and animal models 152
Effect of levamisole on postoperative immunosuppression 151
A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. 151
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily 150
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort 150
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 150
HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact 149
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 148
Endothelial dysfunction in rheumatic autoimmune diseases. 148
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 147
FRI0199 EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 146
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 145
Potential use of TNF-α inhibitors in systemic sclerosis. 144
Fas, Fas ligand, and transfusion immunomodulation 143
Serum zinc levels in patients with multiple myeloma ad waldenstrom's disease 142
Immunohistochemical evidnce of HLA-G expression in extravillous trophoblast invading decidual tissues. 142
Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. 142
Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction 141
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. 141
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. 141
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 141
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 141
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 140
Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. 140
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 140
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients 139
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 139
Current views on diagnostic approach and treatment of lymphedema 139
Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. 137
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 137
Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. 137
Immunogenicity of infliximab and adalimumab 137
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment 136
Il-33/il-31 axis in immune-mediated and allergic diseases 135
Immunoglobulin production pattern is allergen-specific in polysensitized patients. 133
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 133
DsDNA-specific T-cell lines in systemic lupus erythematosus patients: data suggesting their oligoclonality. 133
Accelerated atherosclerosis in patients with Systemic Lupus Erythematosus. 133
Immune homeostasis requires several biologic factors including glucocorticoid hormones 133
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications 133
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. 133
Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. 132
Serum HLA class I antigens: markers and modulators of an immune response? 131
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 130
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 130
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 130
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current evidences upon safety and immunogenicity 130
CD4+ CD25+ T regulatory cells functionin venom imenoptera atopic patients before and during allergen immunotherapy. 129
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? 129
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. 129
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 128
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 128
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 127
Selective TNF-α inhibitor-induced injection site reactions. 126
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 126
Totale 15.657
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.815
article - articoli 69.671
book - libri 506
conference - conferenze 685
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 953
Totale 143.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021117 0 0 0 0 0 0 0 0 0 0 0 117
2021/20222.013 60 166 134 238 60 128 121 479 90 181 100 256
2022/20231.840 167 109 31 188 319 331 2 143 313 13 198 26
2023/2024909 33 162 13 107 64 146 79 71 52 8 56 118
2024/20252.976 103 210 94 185 458 287 293 436 111 115 292 392
2025/20264.779 631 133 263 449 689 479 835 212 310 475 251 52
Totale 22.862